CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension
Executive Summary
With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.
You may also be interested in...
How HALO Slip Proved Costly For CinCor In AstraZeneca Talks
Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.
AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
Mineralys Looks To Path Ahead For MLS-101 In Hypertension
The company plans to meet with the FDA before the end of the year to discuss the way forward, including a pivotal study it hopes to launch in 2023 in uncontrolled and resistant hypertension.